| P50 | author | Jürgen Eberle | Q92285142 |
| P2093 | author name string | Manfred Kunz | |
| | Michael Plötz | |
| | Peter Langer | |
| | Anja Berger | |
| | Martin Hein | |
| | Sandra-Annika Quast | |
| P2860 | cites work | Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis | Q24310597 |
| | GSK-3-selective inhibitors derived from Tyrian purple indirubins | Q27642879 |
| | The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis | Q28213522 |
| | A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry | Q29617253 |
| | Molecular mechanisms of caspase regulation during apoptosis | Q29617861 |
| | Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release | Q33180345 |
| | CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants | Q33195823 |
| | Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors | Q33799792 |
| | Mechanisms and functions of p38 MAPK signalling. | Q34125736 |
| | TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo | Q34256933 |
| | Cellular and molecular biology of human melanoma | Q34779129 |
| | Targeting death and decoy receptors of the tumour-necrosis factor superfamily | Q34791120 |
| | Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China | Q35103342 |
| | The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis | Q35131647 |
| | Apoptosis and melanoma chemoresistance | Q35146577 |
| | TRAIL and apoptosis induction by TNF-family death receptors. | Q35591708 |
| | Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. | Q35897178 |
| | Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide | Q35931968 |
| | p38 MAP kinase's emerging role as a tumor suppressor | Q35941622 |
| | Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy | Q36399234 |
| | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 |
| | Life and death in peripheral T cells | Q36858872 |
| | Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches | Q37022233 |
| | Life and death by death receptors | Q37233180 |
| | Apoptosis induction by Bcl-2 proteins independent of the BH3 domain | Q37263449 |
| | Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells | Q37369672 |
| | Targeting p53 for enhanced radio- and chemo-sensitivity. | Q37406067 |
| | TRAIL and other TRAIL receptor agonists as novel cancer therapeutics | Q37598582 |
| | Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells | Q38513725 |
| | Indirubin shows anti-angiogenic activity in an in vivo zebrafish model and an in vitro HUVEC model | Q39701903 |
| | Synthesis of thia-analogous indirubin N-Glycosides and their influence on melanoma cell growth and apoptosis | Q39743124 |
| | New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue. | Q39792257 |
| | Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway | Q39854847 |
| | Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma | Q39874761 |
| | TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. | Q39906154 |
| | Critical role of Bid and Bax in indirubin-3'-monoxime-induced apoptosis in human cancer cells | Q39996865 |
| | Melanoma epidemiology and trends. | Q40017236 |
| | Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. | Q40126914 |
| | Antitumor activity of novel indirubin derivatives in rat tumor model | Q40187912 |
| | Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. | Q40198109 |
| | Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis | Q40239748 |
| | Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. | Q40265640 |
| | 7-Bromoindirubin-3'-oxime induces caspase-independent cell death | Q40279500 |
| | Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). | Q40349901 |
| | Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer | Q40359028 |
| | Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice | Q40672841 |
| | Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases | Q40918567 |
| | Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease | Q43104154 |
| | Downregulation of c-FLIP, XIAP and Mcl-1 protein as well as depletion of reduced glutathione contribute to the apoptosis induction of glycyrrhetinic acid derivatives in leukemia cells | Q43233411 |
| | XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis | Q44104444 |
| | Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling | Q46580419 |
| | Mitochondria in cell death. | Q50550781 |
| | Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma | Q64376859 |
| | Production of indoxyl derivatives in indole-supplemented tissue cultures of Polygonum tinctorium | Q79658488 |
| | A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies | Q82847250 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 71-81 | |
| P577 | publication date | 2010-09-19 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative--Enhancement of both extrinsic and intrinsic apoptosis pathways | |
| | Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative—Enhancement of both extrinsic and intrinsic apoptosis pathways | |
| P478 | volume | 81 | |